Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.71 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 6/20 | 0.44 |
| ▸ | NPC1 | O15118 | 5/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24862850 | 0.85 | KDM4E (0.67) | KDM4EALDH1A1POLBRAB9ANPC1 | |
| SCHEMBL20858108 | 0.80 | KDM4E (0.61) | KDM4EALDH1A1RAB9ANPC1HPGD | |
| SCHEMBL5373208 | 0.80 | KDM4E (0.71) | KDM4EALDH1A1RAB9ANPC1HPGD | |
| SCHEMBL14759162 | 0.80 | KDM4E (0.71) | KDM4EALDH1A1RAB9ANPC1HPGD | |
| SCHEMBL5359262 | 0.80 | KDM4E (0.71) | KDM4EALDH1A1RAB9ANPC1HPGD | |
| SCHEMBL12797503 | 0.79 | KDM4E (0.70) | KDM4EALDH1A1RAB9ANPC1HPGD | |
| SCHEMBL23959346 | 0.79 | KDM4E (0.65) | KDM4EALDH1A1MAPK14RAB9ANPC1 | |
| Hydrochloric Acid SCHEMBL14759243 | 0.78 | KDM4E (0.69) | KDM4EALDH1A1RAB9ANPC1HPGD | |
| SCHEMBL24273206 | 0.77 | KDM4E (0.67) | KDM4EALDH1A1RAB9ANPC1HPGD | |
| SCHEMBL7983003 | 0.77 | KDM4E (0.67) | KDM4EALDH1A1RAB9ANPC1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11673886-B2 | 5-membered and bicyclic heterocyclic amides as inhibitors of ROCK | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-06-13 | — | — | US | disclosed |
| US-20230167131-A1 | HETEROCYCLIC PAD4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-11 | — | — | US | disclosed |
| US-20210300948-A1 | 1H-PYRROLE-2,5-DIONE COMPOUNDS AND METHODS OF USING THEM TO INDUCE SELF-RENEWAL OF STEM/PROGENITOR SUPPORTING CELLS | Frequency Therapeutics, Inc. | 2021-09-30 | — | — | US | disclosed |
| US-20210213006-A1 | METHODS OF TREATING NEURODEGENERATIVE DISEASES | Seal Rock Therapeutics, Inc. | 2021-07-15 | — | — | US | disclosed |
| US-20210087167-A1 | ASK1 INHIBITOR COMPOUNDS AND USES THEREOF | Seal Rock Therapeutics, Inc. | 2021-03-25 | — | — | US | disclosed |
| US-20210078999-A1 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF | CHARLES RIVER LABORATORIES, INC. | 2021-03-18 | — | — | US | disclosed |
| US-20200308193-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2020-10-01 | — | — | US | disclosed |
| EP-3097092-B1 | FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX | CLEAVE BIOSCIENCES INC (US) | 2020-08-26 | — | — | EP | disclosed |
| WO-2019178191-A1 | O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLYCOPYRANOSIDASE INHIBITORS | BIOGEN MA INC. (US) | 2019-09-19 | — | — | WO | disclosed |
| WO-2011113861-A2 | ARYL AND HETARYL SULFONAMIDES AS ACTIVE AGENTS AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AG (DE) | 2011-09-22 | — | — | WO | disclosed |
| US-7910601-B2 | Heterocyclic aromatic compounds useful as growth hormone secretagogues | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-03-22 | — | — | US | disclosed |
| US-7863291-B2 | Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-01-04 | — | — | US | disclosed |
| US-20100099684-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-22 | — | — | US | disclosed |
| US-20100016233-A1 | Heterocyclic Aromatic Compounds Useful As Growth Hormone Secretagogues | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-01-21 | — | — | US | disclosed |
| US-20090270405-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-29 | — | — | US | disclosed |
| US-7592354-B2 | Heterocyclic aromatic compounds useful as growth hormone secretagogues | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-22 | — | — | US | disclosed |
| EP-1569936-B1 | NOVEL SUBSTITUTED IMIDAZO-PYRIDINONES AND IMIDAZO-PYRIDAZEIONES, THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA (DE) | 2009-03-18 | — | — | EP | disclosed |
| US-20080261970-A1 | Sufonamides and Uses Thereof | ELIXIR PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| WO-2004050658-A1 | NOVEL SUBSTITUTED IMIDAZO-PYRIDINONES AND IMIDAZO-PYRIDAZEIONES, THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099684-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | CHRNA7, CHRNA5, CHRNA6 | KDM4E 3667/4885ALDH1A1 1082/4885POLB 2083/4885 |
| US-11673886-B2 | 5-membered and bicyclic heterocyclic amides as inhibitors of ROCK | MYLK, ROCK1, ROCK2 | KDM4E 507/4885ALDH1A1 3016/4885POLB 4470/4885 |
| US-20210087167-A1 | ASK1 INHIBITOR COMPOUNDS AND USES THEREOF | ATF1, MAP3K1, ROCK1 | KDM4E 1445/4885ALDH1A1 776/4885POLB 3622/4885 |
| US-20210213006-A1 | METHODS OF TREATING NEURODEGENERATIVE DISEASES | SNCA, MAPT, HTT | KDM4E 2231/4885ALDH1A1 2222/4885POLB 2382/4885 |
| US-20100016233-A1 | Heterocyclic Aromatic Compounds Useful As Growth Hormone Secretagogues | GHSR, GHRHR, NPY1R | KDM4E 1038/4885ALDH1A1 3846/4885POLB 4524/4885 |
| US-20090270405-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA5, CHRNA6 | KDM4E 3667/4885ALDH1A1 1082/4885POLB 2083/4885 |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | KDM4E 2437/4885ALDH1A1 312/4885POLB 2269/4885 |
| US-20210300948-A1 | 1H-PYRROLE-2,5-DIONE COMPOUNDS AND METHODS OF USING THEM TO INDUCE SELF-RENEWAL OF STEM/PROGENITOR SUPPORTING CELLS | MCL1, PROX1, MKI67 | KDM4E 1302/4885ALDH1A1 65/4885POLB 1540/4885 |
| US-20200308193-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | BAD, AIFM1, BCL2 | KDM4E 1698/4885ALDH1A1 1587/4885POLB 4580/4885 |
| US-20080261970-A1 | Sufonamides and Uses Thereof | CYP21A2, LPXN, OAT | KDM4E 4113/4885ALDH1A1 569/4885POLB 2539/4885 |
| US-20230167131-A1 | HETEROCYCLIC PAD4 INHIBITORS | PADI4, PADI2, PADI6 | KDM4E 300/4885ALDH1A1 104/4885POLB 617/4885 |
| US-20210078999-A1 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF | KLKB1, KLK1, KLK5 | KDM4E 813/4885ALDH1A1 3007/4885POLB 4667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.